Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients
Copyright © 2022. Published by Elsevier Masson SAS..
Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Journal francais d'ophtalmologie - 45(2022), 9 vom: 26. Nov., Seite 1000-1003 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents |
|---|
| Beteiligte Personen: |
Amblard, M A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.10.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfo.2022.09.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346714044 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346714044 | ||
| 003 | DE-627 | ||
| 005 | 20231226032119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.jfo.2022.09.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346714044 | ||
| 035 | |a (NLM)36155145 | ||
| 035 | |a (PII)S0181-5512(22)00334-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Amblard, M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients |
| 246 | 3 | 3 | |a Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Masson SAS. | ||
| 520 | |a Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO) | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Effets secondaires | |
| 650 | 4 | |a Herpes zoster ophthalmicus | |
| 650 | 4 | |a Moderna | |
| 650 | 4 | |a Pfizer | |
| 650 | 4 | |a Side effects | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a Zona ophtalmique | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 700 | 1 | |a Costantini, E |e verfasserin |4 aut | |
| 700 | 1 | |a Hayek, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ricaud, X |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal francais d'ophtalmologie |d 1993 |g 45(2022), 9 vom: 26. Nov., Seite 1000-1003 |w (DE-627)NLM000357944 |x 1773-0597 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:9 |g day:26 |g month:11 |g pages:1000-1003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfo.2022.09.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 9 |b 26 |c 11 |h 1000-1003 | ||